In this forum, an expert roundtable will discuss the challenges and triumphs of translating science generated within large area educational/research institutions into commercial and therapeutic reality. Achieving this goal requires meeting the unique challenges involved in satisfying the sometimes divergent institutional and commercial interests of the key players involved. The panel will attempt to shed light on these issues that persist in our biotechnology ecosystem.
Those looking to better understand the intricacies and legal processes associated with working with tech transfer offices, academic/industry collaborations, or engaging with large pharma should attend.
MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Senior Advisor to the CEO, Dana-Farber Cancer Institute and Senior Lecturer, Harvard University
Luba is a veteran biotech, pharmaceutical, and healthcare investor and company builder, having recently served in leadership roles at Google Life Sciences and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Luba has led $5B+ in deals and investments across multiple therapeutic areas and life sciences and tech sectors. She has also co-founded biotech and digital health companies in the immunotherapy, women's health and microbiome space, including Incysus and Luca Biologics. Luba serves as a Senior Advisor to the CEO of the Dana-Farber Cancer Institute, lectures at Harvard University in the School of Engineering and Applied Sciences, and advises the Wyss Center for Bio and Neuroengineering. She serves on numerous boards, including the Massachusetts Biotechnology Council (MassBio), Brooklyn ImmunoTherapeutics, and Entrinsic Health. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst, and a Founder of the Pharma Digital Health Roundtable. Luba is also a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology. She has served on numerous non-profit boards including the Longwood Symphony Orchestra, advised on global Covid response efforts, including Covid SafePaths, and has served on Investor Committee for the National Cancer Institute.
Senior Director External Innovation Strategy & Programs, J&J Innovation
Julie is responsible for shaping and implementing the Boston IC strategy for programs and relationships across eastern North America. This includes innovative programs and deployment of business models that bring together all aspects of the innovation community including academia, venture, foundations and startups to create leveraged outreach and funding opportunities that can help expand the portfolio-building efforts and provide frameworks for seeding and de-risking technologies and assets.
Julie has nearly 15 years of experience working in the Boston innovation community including three years at J&J, where she served as the Director of External Alliances for the World Without Disease Accelerator and Lung Cancer Initiatives and previously, the Janssen Human Microbiome Institute. Prior to J&J, Julie held various Program and Alliance Management roles in the Boston ecosystem including leading the Corporate Alliances team at Harvard’s Office of Technology Development. Julie began her biopharmaceutical career at Merck Research Laboratories, Boston, in Drug Metabolism and Pharmacokinetics.
Julie holds an MBA from Boston University and BS from Villanova University.
John A. Harre, is a corporate and licensing attorney at Mintz who focuses his practice on the life sciences. He assists clients in the negotiation and drafting of licensing agreements and strategic collaborations and advises them on business matters involving intellectual property issues, including mergers and acquisitions, investments, and litigation. He primarily works with clients in the biotechnology, pharmaceuticals, and medical devices industries, drawing on 25 years of experience that spans in-house and consulting roles and private practice at several law firms. Prior to rejoining Mintz, John founded an intellectual property and transactional consultancy to advise life sciences companies, served as Vice President of Intellectual Property at Intarcia Therapeutics Inc. and preceding that served as Vice President of Intellectual Property and General Counsel at Archemix Corp. Prior to serving in-house John practiced patent counseling and enforcement at national law firms Sidley Austin, Fish & Richardson and Mintz Levin where he was a Partner in the Life Sciences intellectual property group. John graduated from the University of Missouri - St. Louis with a B.S. in Biology, received his M.S. in Biotechnology from the University of Tennessee - Knoxville and his law degree from the University of New Hampshire Franklin Pierce School of Law (formerly Franklin Pierce Law Center). John is a member of the bar of the Commonwealth of Massachusetts and the State of Texas and is admitted to practice before the United States Patent and Trademark Office. John is a co-chair of the Legal Working Group of the Mass Biotechnology Council and a member of the Dean’s Advisory Council at the University of New Hampshire Franklin Pierce School of Law.
Senior Associate Director for Technology Transactions, Office of Technology Development, Harvard
Kat Holliday is Senior Associate Director for Technology Transactions in Harvard’s Office of Technology Development where her responsibilities include negotiating license and equity agreements for start-up companies forming around Harvard innovations, including those developed at Harvard Medical School, the Harvard Faculty of Arts and Sciences, the Harvard John A. Paulson School of Engineering and Applied Sciences and the Harvard T.H. Chan School of Public Health. Prior to OTD, Kat represented VionX Energy Corporation, a flow-battery, energy storage portfolio company of VantagePoint Capital Partners and Starwood Energy Group. She was previously a senior attorney in both the life sciences and clean energy practice groups at Mintz Levin in Boston, representing venture-backed companies and investors. She is a graduate of Harvard College and Harvard Law School.
Bart Newland is General Counsel of Atalanta Therapeutics, a Series-A funded startup focusing on novel therapies for neurological disorders. Bart previously has served as Senior Vice President and Chief IP Counsel of Biogen, Vice President for Intellectual Property of Genzyme, and as a shareholder of Rothwell, Figg, Ernst & Manbeck. Bart earned his J.D. at William and Mary Law School, where he currently serves on the Board of Directors of the Alumni Association. He earned his B.S. degree with honors in Microbiology from the University of Massachusetts.
Dan Shores is a partner at the law firm Rothwell Figg and focuses on serving biotech, energy, software, and other technology-based companies as they seek to break through and establish themselves in their respective markets. Dan works with clients to build robust patent portfolios, protect trade secrets, forge constructive relationships with strategic partners, and prepare for success in funding rounds and exits. An engineer by education, and having extensive experience in transactional, procurement, strategic counseling, and litigation matters for technology-based companies, Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies and maximizing leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and he is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, United States District Court for the District of Massachusetts, and United States District Court for the District of Columbia.